MTOR and neoplasm: This strong signal with MK2206 is not surprising as ROR1 signaling activates the PI3K/AKT/MTOR pathway [25] and high-level expression of ROR1 may mitigate the anti-tumor activity of an AKT inhibitor in combination with chemotherapy.